Optiver Holding’s Taysha Gene Therapies TSHA Stock Holding History

Optiver Holding’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.02K	Sell	443 -421	-49%	-$2.49K	﹤0.01%	2169
2026 Q1	$3.86K	Sell	864 -70	-7%	-$325	﹤0.01%	1536
2025 Q4	$5.14K	Sell	934 -1,335	-59%	-$6.48K	﹤0.01%	1349
2025 Q3	$7.42K	Buy	2,269 +204	+10%	+$578	﹤0.01%	1476
2025 Q2	$4.77K	Buy	2,065 +1,260	+157%	+$2.74K	﹤0.01%	1208
2025 Q1	$1.12K	Sell	805 -548	-41%	-$917	﹤0.01%	1267
2024 Q4	$2.34K	Buy	1,353 +747	+123%	+$1.55K	﹤0.01%	938
2024 Q3	$1.22K	Buy	+606	New	+$1.33K	﹤0.01%	894

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Optiver Holding's TSHA Position: Q2 2026 in Review

Optiver Holding reduced its Taysha Gene Therapies (TSHA) stake by 49% in Q2 2026, selling an estimated $2.49K and leaving 443 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2169.

Optiver Holding first reported a position in TSHA in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.42K in Q3 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Optiver Holding held 443 shares of Taysha Gene Therapies worth $3.02K as of Q2 2026.
Optiver Holding sold 421 Taysha Gene Therapies shares in Q2 2026, an estimated $2.49K.
Taysha Gene Therapies made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2169 holding.
Optiver Holding first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 8 quarters since.
Optiver Holding's Taysha Gene Therapies position peaked at $7.42K in Q3 2025.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.